派罗欣联合利巴韦林治疗慢性丙肝临床疗效评价

目的探讨派罗欣联合利巴韦林治疗慢性丙肝临床疗效。方法 2010年8月至2012年11月收治的符合入选标准的慢性丙肝病例60例,依据治疗方法不同分为派罗欣组30例,常规治疗组30例,观察两组临床疗效。结果常规治疗组终点应答率50.00%显著低于派罗欣组85.69%,经统计学比较P〈0.05差异有统计学意义;派罗欣组持续应答率69.29%,常规治疗组持续应答率52.15%两组比P〉0.05差异无统计学意义。结论通过对两组病例进行观察,应用普通干扰素常规组终点应答率50.00%显著低于派罗欣组85.69%;持续应答率两组比较无显著差异,两组不良反应发生率相近,差异无统计学意义;派罗欣在慢性丙型病毒性肝炎治疗中疗效更为确切,与普通干扰素比较安全性相当,并且具有使用方便每周一次,提高了患者依从性。

Pegasys combined with Ribavirin in the treatment of chronic hepatitis C clinical evaluation

Objective To investigate the clinical curative effect of Pegasys combined with ribavirin in the treatment of chronic hepatitis C..Methods In total,60 patients,conformed to the inclusion criteria of chronic hepatitis C,according to the different treatment methods,were divided into two groups： Pegasys group（30 cases）,the conventional treatment group（30 cases）,Then observed the clinical curative effect of two groups.Results Conventional treatment group end a response rate of 50% was significantly lower than that of Pegasys groups after statistical comparison of 85.69%,there was significant difference（P 0.05）;Pegasys groups sustained response rate was 69.29%,the conventional treatment group the sustained response rate was 52.15% there was no significant difference（P 0.05）.Conclusion The two groups were observed,using conventional group end of interferon response rate of 50% was significantly lower than that of Pegasys groups of 85.69%;the sustained response rate between the two groups had no significant difference between the two groups,the incidence of adverse reactions were similar,no significant difference;Pegasys in chronic C hepatitis therapy more for the exact,and ordinary interferon comparative safety,and has the advantages of convenient use once a week,and improve the compliance in patients.